The Target Discovery Institute, Oxford (www.tdi.ox.ac.uk/home) is a research facility dedicated to identifying drug targets, molecules or molecular interactions at a critical point in a disease-causing pathway that are predicted to being amenable to therapeutic manipulation. The instituted has been operating since 2013 in the NDMRB on the Old Road Campus and is directed by Professor Sir Peter Ratcliffe. The TDI consists of eight Principal Investigators with particular expertise in High Throughput screening (Ebner, Fedorov), Functional Genomics (Nijman), Chemical Biology (Huber), Medicinal Chemistry (Brennan), Proteomics (Kessler), and Biomedical Imaging (Rittscher).

In this talk, we will highlight a number of techniques we use to advance target discovery including, cell based screening (including CRISPR/Cas9), chemo-proteomics, chemical biology and multi-omics with group leaders, Ebner, Kessler and Huber. We will also discuss some of the technology platforms we employ, some recent success stories and finally, discuss opportunities for scientific collaboration with the TDI.